Skip to main content
SRTA
NASDAQ Industrial Applications And Services

Strata Secures $30M Revolving Credit Facility to Fund Acquisitions and Working Capital

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$4.562
Mkt Cap
$405.059M
52W Low
$2.35
52W High
$6.02
Market data snapshot near publication time

summarizeSummary

Strata Critical Medical, Inc. secured a new $30.0 million asset-based revolving credit facility, expandable to $50.0 million, to bolster working capital and support its acquisition strategy, while keeping its aircraft unencumbered.


check_boxKey Events

  • Secured Revolving Credit Facility

    The company entered into a Credit Agreement for a secured, asset-based revolving credit facility (ABL Facility) of up to $30.0 million, with JPMorgan Chase Bank, N.A. as the administrative agent.

  • Expansion Potential

    The ABL Facility may be increased by up to an aggregate of $20.0 million, bringing the total potential facility size to $50.0 million, subject to certain conditions.

  • Strategic Use of Proceeds

    The facility will be used for working capital, general organizational purposes, and to support future acquisitions, enhancing the company's capital efficiency.

  • Unencumbered Aircraft Fleet

    Owned aircraft are explicitly excluded from the collateral package, maintaining significant optionality for additional financing in the future.


auto_awesomeAnalysis

Strata Critical Medical, Inc. has entered into a significant asset-based revolving credit facility, providing up to $30.0 million in immediate liquidity, with the potential to expand to $50.0 million. This capital infusion is crucial for supporting the company's working capital needs and, more strategically, for funding future acquisitions. The facility is secured by personal property of the loan parties, but notably, the company's owned aircraft fleet remains unencumbered, preserving flexibility for additional financing options. This move signals a proactive approach to financial management and growth, especially given the company's stated strong track record in tuck-in acquisitions within the clinical perfusion space. The terms, including a SOFR-based interest rate and a 0.25% commitment fee on the unused portion, are customary for such facilities, and the springing Fixed Charge Coverage Ratio covenant provides a safety net for lenders.

At the time of this filing, SRTA was trading at $4.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $405.1M. The 52-week trading range was $2.35 to $6.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SRTA - Latest Insights

SRTA
Apr 16, 2026, 5:31 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
SRTA
Apr 14, 2026, 8:54 AM EDT
Filing Type: DEF 14A
Importance Score:
8
SRTA
Apr 08, 2026, 5:03 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
SRTA
Apr 07, 2026, 5:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
SRTA
Mar 03, 2026, 11:52 AM EST
Filing Type: 10-K
Importance Score:
8
SRTA
Mar 03, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
SRTA
Feb 05, 2026, 9:09 AM EST
Filing Type: 8-K
Importance Score:
8